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Abstract
AIM: To investigate the effects of Saccharomyces 
boulardii  (S. boulardii ) in an experimental rat model of 
trinitrobenzene sulfonic acid (TNBS)-induced colitis.
METHODS: Thirty-two Wistar albino female rats were 
categorized into five groups. On the first day of the 
study, 50 mg TNBS was administered via  a rectal cath-
eter in order to induce colitis in all rats, except those in 
the control group. For 14 d, the rats were fed a stan-
dard diet, without the administration of any additional 
supplements to either the control or TNBS groups, in 
addition to 1 mg/kg per day S. boulardii  to the S. bou-
lardii  group, 1 mg/kg per day methyl prednisolone (MP) 
to the MP group. The animals in the S. boulardii  + MP 
group were coadministered these doses of S. boulardii  
and MP. During the study, weight loss, stool consis-
tency, and the presence of obvious blood in the stool 
were evaluated, and the disease activity index (DAI) for 
colitis was recorded. The intestines were examined and 
colitis was macro- and microscopically scored. The se-
rum and tissue levels of tumor necrosis factor-α (TNF-α) 
and nitric oxide (NO) were determined, and fungemia 
was evaluated in the blood samples.
RESULTS: The mean DAI scores for the MP and S. 
boulardii  + MP groups was significantly lower than the 
TNBS group (3.69 ± 0.61 vs  4.46 ± 0.34, P  = 0.018 
and 3.77 ± 0.73 vs  4.46 ± 0.34, P  = 0.025, respective-
ly). While no significant differences between the TNBS 
and the S. boulardii  or MP groups could be determined 
in terms of serum NO levels, the level of serum NO in 
the S. boulardii  + MP group was significantly higher 
than in the TNBS and S. boulardii  groups (8.12 ± 4.25 
μmol/L vs  3.18 ± 1.19 μmol/L, P  = 0.013; 8.12 ± 4.25 
μmol/L vs  3.47 ± 1.66 μmol/L, P  = 0.012, respec-
tively). The tissue NO levels in the S. boulardii , MP and 
S. boulardii  + MP groups were significantly lower than 
the TNBS group (16.62 ± 2.27 μmol/L vs  29.72 ± 6.10 
μmol/L, P  = 0.002; 14.66 ± 5.18 μmol/L vs  29.72 ± 6.10 
μmol/L, P  = 0.003; 11.95 ± 2.34 μmol/L vs  29.72 ± 6.10 
μmol/L, P  = 0.002, respectively). The tissue NO levels 
in the S. boulardii , MP and S. boulardii  + MP groups 
were similar. The mean serum and tissue TNF-α levels 
were determined to be 12.97 ± 18.90 pg/mL and 21.75 
± 15.04 pg/mL in the control group, 18.25 ± 15.44 
pg/mL and 25.27 ± 11.95 pg/mL in the TNBS group, 
20.59 ± 16.15 pg/mL and 24.39 ± 13.06 pg/mL in the S. 
boulardii  group, 9.05 ± 5.13 pg/mL and 24.46 ± 10.85 
pg/mL in the MP group, and 13.95 ± 10.17 pg/mL and 
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Significant differences in terms of the levels of serum 
and tissue TNF-α and the macroscopic and microscopic 
scores were not found between the groups. S. boulardii  
fungemia was not observed in any of the rats. However, 
Candida  fungemia was detected in one rat (14%) in the 
TNBS group, two rats (28%) in the S. boulardii  group, 
three rats (50%) in the MP group, and three rats (42%) 
in S. boulardii  + MP group.
CONCLUSION: S. boulardii  does not demonstrate 
considerable effects on the DAI, pathological scores, or 
cytokine levels but does decrease the tissue NO levels.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
It is currently speculated that inflammatory bowel disease 
(IBD) develops in genetically prone individuals as a result 
of  defective immune responses against enteric bacterial 
flora antigens. Antibiotics and immunomodulatory thera-
pies are believed to play an important role in the treat-
ment of  this disease[1].
Probiotics are live microorganisms that positively aff- 
ect health when ingested. Saccharomyces boulardii (S. bou-
lardii) is a thermophilic nonpathogenic yeast that is se-
lectively used to treat antibiotic-associated and traveler’s 
diarrhea[2]. The main mechanisms of  action of  S. boular-
dii include antimicrobial activities, trophic effects upon 
the intestinal mucosa, and the modification of  the host-
signaling pathways that are involved in inflammatory and 
noninflammatory intestinal diseases. It has been shown 
that S. boulardii inhibits the production of  proinflam-
matory cytokines by inhibiting the main regulators of  
inflammation, such as nuclear factor κB and mitogen-
activated protein kinases, which play crucial roles in the 
pathogenesis of  IBD[3,4]. S. boulardii is believed to ef-
fectively treat IBD because of  its antimicrobial activities 
and its regulatory effects on enteric flora and the immune 
system[5]. In a recent study[6], it was shown that treating 
human colon epithelial cells with S. boulardii increases the 
expression of  peroxisome proliferator-activated recep-
tor-c and the secretion of  inhibits interleukin-8 (IL-8). 
In the same study, it was demonstrated that S. boulardii 
decreases intestinal inflammation by reducing the muco-
sal expression of  proinflammatory cytokines in rats with 
trinitrobenzene sulfonic acid (TNBS)-induced colitis. 
This earlier study demonstrates that colonic inflammation 
can be reduced by S. boulardii through the regulation of  
inflammatory gene expression.
Nitric oxide (NO) is an important messenger that 
is involved in vein permeability and tissue damage. It is 
possible that in patients with active ulcerative colitis (UC) 
and Crohn’s disease (CD), the inducible activity of  NO 
synthase is elevated in inflamed mucosal epithelial cells. 
Increased NO levels indicate inflammation and, in turn, 
the intensity of  the disease. Variations in tissue NO levels 
are important indicators of  progression and recovery 
from IBD. There is also evidence that S. boulardii inhibits 
inducible nitric oxide synthase[7].
In the current literature, there are studies suggest-
ing that S. boulardii causes fungemia, particularly in im-
munosuppressed and intensive care patients[8]. However, 
controlled studies cannot be used to investigate the effec-
tiveness of  S. boulardii against IBD, although promising 
results have been reported in a few studies[9,10].
The primary aim of  our present study was to inves-
tigate the effects of  S. boulardii on colonic inflammation 
and the disease activity index (DAI) in a rat model of  
TNBS-induced colitis. The secondary purpose of  our 
current analyses was to investigate the risk of  fungemia 




Approval was obtained from the animal ethics council of  
Dokuz Eylul University Medical Faculty (DEUTF). The 
DEUTF Hospital Experimental Research Laboratory 
provided 32 female Wistar albino rats weighing 200-250 g 
for use in this study which were divided into five groups. 
The control group included only four rats that were not 
treated with TNBS. All other groups consisted of  seven 
rats (Table 1).
The rats were maintained in a room at a temperature 
of  23 ± 2 ℃ under a 12-h light/dark cycle at the DEUTF 
Experimental Animal Laboratory. Prior to and during the 
study, the rats were fed a standard diet (Yemta; Taris Ltd. 
Şti., Izmir, Turkey), and their weights were monitored 
daily. The rats were allowed water ad libitum.
Induction of colitis
After 24 h of  fasting, 0.5 mL physiological serum was 
intracolonically administered to the rats in the control 
group via a cannula that was placed 8 cm proximal to 
the anus using a rectally inserted flexible polypropylene 
catheter. To induce colitis in the other groups, the rats 
were intracolonically treated with 0.5 mL of  100 mg/mL 
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TNBS that was dissolved in 50% ethanol and adminis-
tered via a cannula. Prior to catheter insertion, short-term 
sedation was provided via ether anesthesia. After TNBS 
administration, no rats developed perforation or exitus 
due to the formation of  ulcerations in the colon.
Experimental design
As shown in the Table 1, 32 Wistar albino female rats 
were divided into five groups. The rats in the control 
group (n = 4) were not treated with TNBS after the in-
tracolonic administration of  physiological serum (via a 
cannula placed 8 cm proximal to the anus using a rectally 
inserted polypropylene catheter, similar to the administra-
tion of  TNBS). After the administration of  TNBS, the 
rats in the TNBS group (n = 7) were not treated. S. bou-
lardii (Reflor; Biocodex laboratories, Gentilly, France) was 
prepared in its lyophilized form (282.5 mg/sachet with a 
biological activity of  5 × 109 viable cells) by the manufac-
turer. S. boulardii (1 mg/kg per day) was suspended in dis-
tilled water and added to the water supply of  the rats in 
the S. boulardii group (n = 7) in the morning and evening 
starting on day 0. The rats in methyl prednisolone (MP) 
group (n = 7) were treated with MP (Prednol; Mustafa 
Nevzat, Istanbul, Turkey) at a dosage of  1 mg/kg per day, 
while the rats in the S. boulardii + MP group (n = 7) were 
treated with both S. boulardii and MP at the previously de-
fined dosages using the previously discussed techniques.
Disease activity index 
TNBS-induced colitis was scored according to the DAI 
proposed by Murthy et al[11] (Table 2). Scoring was calcu-
lated according to body weight loss (as a percentage), dif-
ferences in stool consistency, and the occurrence of  rec-
tal bleeding. Fecal occult blood testing (FOBT) of  stool 
samples (Hemoccult II; Beckman Coulter Inc., Fullerton, 
CA, United States) was used to detect obscure bleeding.
Pathological examination
After 14 d, blood was drawn from the abdominal aorta 
under ether anesthesia following 24 h of  fasting, and 
then the rats were sacrificed due to hypovolemia. Decapi-
tation was performed after tissue samples were collected 
for pathological examination. The abdominal cavity was 
opened via a midline incision, and the whole small and 
large intestines were harvested from the pylorus to the 
rectum. The intestinal lumen was washed with physi-
ological serum containing phosphate buffer (PBS), and 
the intestinal materials collected from the opened lumen 
was fixed in formaldehyde. A pathologist who was blind 
to the groups conducted the pathological examinations 
of  the intestinal samples.
The scoring method defined by Wallace et al[12] was 
used to evaluate damage due to colonic inflammation. 
Fixed intestinal tissue samples were microscopically 
examined (5 × magnification) and scored from 0-10 ac-
cording to various inflammation markers, such as the 
diameters of  any developing ulcers, thickening of  the 
intestinal wall, and hyperemia. While intestinal tissues 
without any evidence of  lesions were scored as 0, intes-
tinal tissues with serious ulcerations were scored as 10. 
Subsequently, histological sections, including the periph-
eral normal mucosa, were prepared from gross ulcerative 
lesions. Approximately 1-cm sections were obtained from 
the intestines and transported on ice to the Department 
of  Clinical Microbiology (DEUTF, Izmir, Turkey) for 
homogenization before fixation in formaldehyde. The 
tissues were fixed in formaldehyde, embedded in paraf-
fin, and stained with hematoxylin and eosin. For the 
microscopic evaluation, we employed the defined scoring 
system described by Ameho et al[13].
Tissue homogenization
Prior to sacrifice, blood samples were drawn from the 
vena cava under ether anesthesia, and the serum was 
separated by centrifugation and stored at -70 ℃ until use. 
Homogenization of  the intestinal tissues was performed 
in accordance with current methods[14]. The intestinal 
tissues were first homogenized in an ice-cold buffer [0.1 
mol/L potassium phosphate (pH 7.5) and 20 mmol/L 
ethylene diamine tetra acetic acid (EDTA), 1:10 w/v] us-
ing a mechanical homogenizer (Potter B. Braun; Gemini, 
Apeldoorn, The Netherlands) and then in an ultrasonic 
homogenizer on ice. The resulting lysates were centri-
fuged at 14  000 rpm for 10 min followed by an additional 
spin at 14  000 rpm for 20 min. The proteins were puri-
fied using zinc sulfate (300 g/L) at a 1:20 ratio, and the 
final sample concentration of  15 g/L was obtained via 
centrifugation. The final products were centrifuged at 
4 ℃ for 20 min at 2000 rpm, and 100-μL samples were 
subsequently prepared for evaluation of  cytokine and 
NO levels.
NO analysis
The 100-μL intestinal tissue lysates and serum samples 
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Table 1  Study groups
Group n Application (day 1) Application (days 1-14)
Control 4 Physiological 
serum
Physiological serum
TNBS 7 TNBS No treatment
S. boulardii 7 TNBS S. boulardii
MP 7 TNBS MP
S. boulardii + MP 7 TNBS S. boulardii + MP
TNBS: Trinitrobenzene sulfonic acid; S. boulardii: Saccharomyces boulardii; 
MP: Methyl prednisolone. 
Table 2  Disease activity index analysis1
Score Weight loss (%) Stool consistency Rectal bleeding
0 - Normal -
1 1-5 Loose stool Occult blood in stool
2   5-10 Loose stool Occult blood in stool 
3 10-20 Loose stool Occult blood in stool 
4 > 20 Watery stool Obvious blood in stool
1Data are reported by Murthy et al [11].  
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on day 3 and had returned to normal by day 9. However, 
in the S. boulardii + MP group, the stool returned to nor-
mal by day 10 after becoming loose on day 2. The MP 
and S. boulardii + MP groups demonstrated 9 and 10 d of  
diarrhea, respectively (Figure 1A).
While defecation in the TNBS and S. boulardii groups 
macroscopically continued for an average of  9 and 7 d, 
respectively, in the following days the FOBT results were 
positive until day 14. In the MP group, bloody defecation 
was observed for an average of  three days, while for the 
following six days the FOBT results were positive even 
without clearly noting bloody defecation. In addition, the 
blood in the stool was, on average, not observed until day 
9. In the S. boulardii + MP group, bloody stool was ob-
served for an average of  two days, and the FOBT results 
were positive for seven days; however, there was no trace-
able blood in the stool samples after day 9 (Figure 1B).
The rats in the control group gained an average of  
4.3 g in weight, those in the TNBS and S. boulardii groups 
gained an average of  11.9 and 2.4 g, respectively, and the 
rats in the MP and S. boulardii + MP groups lost 3 and 5.9 
g, respectively. No significant differences in body weight 
changes could be determined between the S. boulardii, 
MP, and S. boulardii + MP groups. There were significant 
differences in body weight changes for the MP and S. 
boulardii + MP groups compared with the TNBS group (P 
= 0.01 and 0.02, respectively) (Table 3).
Based on the scoring system that was previously sug-
gested by Murthy et al[11], DAI scores were 1 ± 0 for the 
control group, 4.46 ± 0.34 for the TNBS group, 4.07 ± 
0.77 for the S. boulardii group, 3.69 ± 0.61 for the MP 
group, and 3.77 ± 0.73 for the S. boulardii + MP group. 
The DAI scores of  the MP and S. boulardii + MP groups 
were significantly lower compared with the TNBS group 
(P = 0.018 and 0.025, respectively). Regarding the other 
groups, no significant differences in DAI could be deter-
mined (Figure 1C).
Pathological evaluation
Macroscopic ulceration was not observed in the control 
group, although inflammation was observed at the micro-
scopic level. Upon macroscopic examination, a 14-mm 
ulcer in the intestinal tissue was observed in one rat in 
the TNBS group, while 3, 2, and 3 larger ulcers (> 2 cm) 
were observed in the S. boulardii, MP, and S. boulardii + 
MP groups, respectively. After macroscopic and micro-
scopic scoring, of  all the groups that were induced to 
form colitis, the lowest score was observed in the TNBS 
group. When the treated groups were examined, the S. 
boulardii group demonstrated the lowest scores, although 
significant differences were not found between the MP 
and S. boulardii + MP groups (Figure 1D). 
Serum and tissue NO levels
The mean serum NO levels in the control, TNBS, S. bou-
lardii, MP, and S. boulardii + MP groups were determined 
to be 5.92 ± 3.65 μmol/L, 3.18 ± 1.19 μmol/L, 3.47 
± 1.66 μmol/L, 8.22 ± 6.28 μmol/L, and 8.12 ± 4.25 
were mixed with an equal volume of  100 μL of  Griess 
reagent (Ingredient A: 0.1% naphthalene diamine dihy-
drochloride at a final concentration of  5 mmol/L; Ingre-
dient B: 1% sulfanilamide at a final concentration of  5 
mmol/L in orthophosphoric acid) in a 96-well microtiter 
plate (Maxisorb Immunoplate; NUNC, Roskilde Den-
mark). After incubation for 10 min at room temperature, 
the absorbance at 540 nm was measured using a mi-
croplate reader (Reader Model 230S; Organon Teknika, 
Boxtel, The Netherlands). For each measurement, 2-fold 
increases in sodium nitrite in PBS, from 0-128 mmol/L, 
were used to generate a standard curve[15].
Tumor necrosis factor-α analysis
Serum and tissue tumor necrosis factor (TNF)-α levels 
were measured using a commercially available rat-specific 
enzyme-linked immunosorbent assay kit according to the 
manufacturer’s instructions (Invitrogen; Life Technolo-
gies, Camarillo, CA, United States).
Fungal isolation and identification
Blood samples were cultured in Petri dishes containing 
the following culture media: Sabouraud dextrose agar 
(BD Difco; Becton, Dickinson, NJ, United States) sup-
plemented with 100 mg/L chloramphenicol and selective 
CHROMagar Candida (CHROMagar Candida; CHRO-
Magar, Paris, France). Following incubation at 30 ℃ for 
72 h, the yeast colonies were visually quantified, if  they 
existed. A specimen from each colony variant was placed 
in a tube containing Sabouraud dextrose agar for stor-
age and identification. Identification was based on the 
results of  filament production tests; the production of  
the germinative tube, ascospores, urease, and phenoloxi-
dase; and zymogram, auxanogram, and growth rates at 
different incubation temperatures, as recommended by 
Boekhout et al[16,17].
Statistical analysis
Statistical analyses were conducted using SPSS software 
for windows 11.0 (SPSS, Chicago, IL). Data are expressed 
as the mean ± SD. Quantitative data, such as the mac-
roscopic and microscopic scores and NO and TNF-α 
levels, were compared between groups using the Kruskal-
Wallis and Mann-Whitney U tests. Differences between 




We did not observe diarrhea or bloody stool in the four 
rats in the control group during the course of  this study 
but these effects were observed in 27 rats starting on day 
1, plus one rat on day 2, following the administration of  
TNBS. In the TNBS and S. boulardii groups, a loose stool 
was noted on day 7 and never returned to normal and 
diarrhea persisted for a total of  14 d over the course of  
this study. In the MP group, a loose stool was observed 
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μmol/L, respectively. The lowest serum NO levels were 
observed in the TNBS and S. boulardii groups. The serum 
NO levels in S. boulardii + MP group were higher than 
those in the TNBS and S. boulardii groups (P = 0.013 and 
0.012, respectively).
The mean tissue NO levels in the control, TNBS, S. 
boulardii, MP, and S. boulardii + MP groups were deter-
mined to be 7.95 ± 0.50 μmol/L, 29.72 ± 6.10 μmol/L, 
16.62 ± 2.27 μmol/L, 14.66 ± 5.18 μmol/L, and 11.95 
± 2.34 μmol/L, respectively. The highest tissue NO level 
was observed in the TNBS group. The tissue NO levels 
in the S. boulardii, MP, and S. boulardii + MP groups were 
significantly lower in comparison with the TNBS group 
(P = 0.002, 0.003 and 0.002, respectively). However, the 
tissue NO levels in the S. boulardii, MP, and S. boulardii + 
MP groups were similar (Figure 2A).
Serum and tissue TNF-α levels
The mean serum TNF-α levels were determined to be 
12.97 ± 18.90 pg/mL in the control group, 18.25 ± 15.44 
pg/mL in TNBS group, 20.59 ± 16.15 pg/mL in S. bou-
lardii group, 9.05 ± 5.13 pg/mL in MP group, and 13.95 
± 10.17 pg/mL in S. boulardii + MP group. The mean 
tissue TNF-α levels were determined to be 21.75 ± 15.04 
pg/mL in the control group, 25.27 ± 11.95 pg/mL in 
TNBS group, 24.39 ± 13.06 pg/mL in S. boulardii group, 
24.46 ± 10.85 pg/mL in MP group, and 24.26 ± 10.37 
pg/mL in S. boulardii + MP group. The serum and tissue 
TNF-α levels were comparable between groups (Figure 
2B). 
Detection and identification of fungal pathogens
Fungemia was not observed in the control group but was 
detected in 1 of  7 rats (14%) in the TNBS group, 2 of  
7 rats (28%) in the S. boulardii group, 3 of  6 rats (50%) 
in the MP group (1 rat in the MP group was excluded 
because sufficient blood samples could not be obtained), 
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Figure 1  Daily defecation trends, rectal bleeding scores, disease activity index analyses, macro- and microscopic pathological scores of the experimental 
groups. A: Daily defecation trends; B: Rectal bleeding scores; C: Disease activity index analyses; The results are shown as the mean ± SD. aP = 0.018 between 
trinitrobenzene sulfonic acid (TNBS) and methyl prednisolone (MP) group; cP = 0.025 between TNBS and Saccharomyces boulardii (S. boulardii) and TNBS group; D: 
Macro- and microscopic pathological scores. The results are shown as the mean ± SD. DAI: Disease activity index.
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fungemia was determined to be Candida fungi other than 
C. albicans using an identification process as explained in 
materials and methods section. S. boulardii fungemia was 
not identified in any of  the rats.
DISCUSSION
It is thought that IBD develops in genetically prone indi-
viduals as a result of  defective immune responses against 
the antigens of  enteric bacterial flora. Antibiotics and im-
munomodulatory therapies are believed to be important 
for the treatment of  these diseases[1]. S. boulardii is a pro-
biotic yeast, and it is known that probiotics inhibit patho-
genic invasion and also demonstrate regulatory effects on 
the enteric flora and immune system[2-5]. Although there 
are several published studies on probiotic bacterial thera-
pies in experimental animals with induced IBD, there are 
only a few studies on S. boulardii. In this study, the ef-
fectiveness of  S. boulardii, DAI, macro- and microscopic 
pathological ulcer scores, proinflammatory cytokine levels 
(i.e., serum and tissue levels of  TNF-α), and the serum 
and tissue levels of  lipid peroxidation products (i.e., NO) 
were evaluated.
In our study, the DAI in the groups that were admin-
istered individual MP or MP with S. boulardii were evalu-
ated at significantly lower levels compared with the TNBS 
group. Meaningful differences in the DAI scores of  the 
S. boulardii group were not determined, although the DAI 
score of  the S. boulardii group was lower than that of  the 
TNBS group. As expected, these results show that the 
treatment of  colitis using MP effectively improves the 
symptoms that are observed in rat models of  induced 
colitis. However, the DAI scores were comparable be-
tween the MP and S. boulardii + MP groups, suggesting 
that the application of  MP in combination with S. boular-
dii might not be more effective than the individual appli-
cation of  MP. In a recent study[18], Lactobacillus and Bifido-
bacterium were used to prevent colitis in rats using dextran 
sodium sulfate, and DAI scores in the probiotic-treated 
group were lower than the control group. However there 
are no other reported studies that have investigated the 
effects of  S. boulardii on DAI in an experimental model 
of  colitis.
There are a few clinical studies on the application of  S. 
boulardii for the treatment of  UC and CD patients. Gus-
landi et al[9] conducted a study using 32 CD patients who 
were medically treated and had been in remission for 3 
mo. For 6 mo, a group was administered only mesalamine 
(3 g/d) and another group was administered mesalamine 
(2 g/d) and S. boulardii (1 g/d). After 6 mo, 10 patients 
in the mesalamine-treated group and 15 patients from 
the mesalamine + S. boulardii-treated group were still in 
remission (P < 0.04). The same researchers conducted 
another pilot study[10] on 25 patients with UC of  mild/
moderate intensity who could not be treated with corti-
costeroids. After 3 mo of  mesalamine (3 g/d) treatment, 
the patients were additionally supplemented with S. bou-
lardii (250 mg administered 3 × per day) for 4 wk. At the 
end of  treatment, 17 patients (68%) were in remission 
and had demonstrated an obvious reduction in their clini-












































































Figure 2  Serum and tissue nitric oxide and tumor necrosis factor-α levels of the experimental groups. A: Serum and tissue nitric oxide levels; B: Serum and 
tissue tumor necrosis factor (TNF)-α levels. The results are shown as the mean ± SD. aP < 0.05 vs Saccharomyces boulardii (S. boulardii) + methyl prednisolone (MP); 
cP < 0.05 vs trinitrobenzene sulfonic acid (TNBS). NO: Nitric oxide. 
Table 3  Changes in body weight in the experimental groups
Groups Baseline weight Final weight Difference in 
body weight
Control   214.0 ± 18.4   218.25 ± 19.6    4.3
TNBS   218.1 ± 18.6     230.0 ± 17.9  + 11.9a,b
S. boulardii 195.6 ± 9.1     198.0 ± 20.2 + 2.4
MP 199.3 ± 9.1 196.33 ± 9.1  - 3.0
S. boulardii + MP   197.3 ± 10.7 191.43 ± 9.1  - 5.9
The results are shown as the mean ± SD. aP = 0.02 vs Saccharomyces 
boulardii (S. boulardii) + methyl prednisolone (MP); bP = 0.01 vs MP. TNBS: 
Trinitrobenzene sulfonic acid. 
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boulardii was not used alone and a control group was not 
evaluated.
In our study, macroscopic and microscopic patho-
logical scoring was performed to evaluate the effec-
tiveness of  S. boulardii against colonic inflammation. 
Statistically significant differences were not observed 
between the treated and untreated groups that were 
induced to form colitis. In addition, no improvement 
was noted in the colon mucosa following the administra-
tion of  individual applications of  MP and S. boulardii or 
the dual application of  MP and S. boulardii. However, 
the use of  probiotics, such as Lactobacillus and VSL#3 
(contains one strain of  streptococcus thermophilus, three 
strains of  bifidobacterium and four strains of  lactobacillus), 
for the treatment TNBS-induced colitis in rat models 
have demonstrated significant improvements in macro-
scopic and microscopic scores[19,20]. Surprisingly, in our 
study, the macroscopic scores in the S. boulardii, MP, 
and S. boulardii + MP groups were higher, although they 
were not significantly different when compared with the 
TNBS group. In the MP and S. boulardii + MP groups, 
the macroscopic and microscopic pathology scores were 
higher than in the TNBS group, although these groups 
also demonstrated significantly lower DAI scores. Thus, 
these results suggest that the clinical responses are not 
consistent with the histopathological results. The higher 
macroscopic and microscopic pathology scores in the 
treatment groups compared with the TNBS group can 
be explained by delayed effects in ulcer improvement 
due to fungal colonization in the gastrointestinal (GI) 
tract. In our study, non-Candida albicans fungemia was de-
tected at considerable frequencies in the treated groups. 
In a study[21] on inhibiting Candida translocation in the 
GI tract using probiotics, a group of  patients with UC 
and rats with acetic acid-induced stomach ulcers were 
included. It was shown that Candida colonies formed in 
these groups, which was accompanied by the delayed 
recovery of  stomach ulcers and the persistence of  both 
of  gastric ulcers and UC symptoms. An increase in cy-
tokine expression, especially TNF-α and IL-1 levels, was 
detected in the rats that were inoculated with Candida. 
IBD is an immunosuppressive disease caused by a 
defective intestinal mucosal barrier that can be brought 
on by applied treatments. Thus, during the course of  the 
disease, insidious infections, such as cytomegalovirus 
and C. albicans, can develop. There are reported cases of  
the development of  fungemia caused by Candida species, 
such as C. parapsilosis, C. albicans, and Saccharomyces cerevi-
siae, in UC patients. S. boulardii fungemia was reported in 
a 33-year-old male patient who was diagnosed with IBD, 
underwent intestinal surgery, and was in the intensive 
care unit[22]. In our study, fungemia due to S. boulardii did 
not develop in any of  the groups. Accordingly, in the 
colitis rat model, an increase in the risk of  developing S. 
boulardii fungemia was not determined upon the applica-
tion of  S. boulardii alone or in conjunction with MP. In 
this study, while fungemia was not observed in the con-
trol group, non-C. albicans was observed in the TNBS, S. 
boulardii, MP, S. boulardii + MP groups with frequencies 
of  14%, 28%, 50%, and 48%, respectively. This result is 
not consistent with previously published reports on the 
inhibition of  Candida translocation in the gastrointestinal 
tract due to the use of  probiotics in immunosuppressed 
rats[21,23].
In this study, the serum NO level in the group 
treated with S. boulardii + MP was high compared with 
the TNBS and S. boulardii groups. In addition, serum 
NO levels were comparable between the other groups. 
However, tissue NO levels in all 3 treatment groups were 
statistically and significantly lower in comparison with 
the TNBS group. As observed, the serum and tissue NO 
levels were inconsistent. However, it is known that the 
serum NO level is affected by systemic events, and tis-
sue NO levels are more reliable. As a result, based on the 
results of  the TNBS group, tissue NO levels are found 
to be low in all treatment groups. These results suggest 
that use of  S. boulardii and MP alone or in combination 
can reduce the intensity of  inflammation and damage to 
the colitis mucosa. It was also revealed that the addition 
of  S. boulardii to MP treatment does not yield a synergis-
tic effect because the tissue NO levels of  the MP and S. 
boulardii + MP groups were similar. In another study[7], 
S. boulardii treatment reportedly affected NO levels in a 
rat diarrhea model that was induced by castor oil. In that 
study, S. boulardii was a successful diarrhea treatment that 
inhibited inducible NO synthase activity. In addition, 
other probiotics, especially Lactobacillus that has been used 
in induced colitis models, have been reported to reduce 
the tissue NO level by inhibiting inducible NO synthase 
activities[24].
TNF-α is produced by CD4 + T lymphocytes that are 
assembled around inflamed mucosa. TNF-α is a strong 
chemokine that functions in pathological inflammatory 
signal transduction by directing the migration of  neutro-
phils to inflamed mucosa. Therefore, serum and tissue 
TNF-α levels are mainly used to evaluate the intensity of  
inflammation. In many studies conducted using Lactoba-
cillus in TNBS-induced colitis models, the tissue TNF-α 
levels in the groups that were administered Lactobacillus 
were significantly reduced compared with the control 
group[25,26]. It has been demonstrated that the Lactobacillus 
species used in those studies reduces the number of  CD4 
+ T cells in inflamed mucosa, thus reducing TNF-α pro-
duction. In addition to these effects, Lactobacillus increases 
the production of  anti-inflammatory IL-10 by shifting 
the T helper1 (Th1) cellular immune response towards 
Th2 and Th3. By changing the TNF-α/IL-10 ratio, the 
intensity of  inflammation can be reduced[26]. In a recent 
study[6], it was demonstrated that S. boulardii decreases in-
testinal inflammation by reducing the mucosal expression 
of  proinflammatory cytokines in rats with TNBS-induced 
colitis. In our study, the serum and tissue TNF-α levels 
were similar in all groups. These results can be explained 
by non-Candida albicans fungemia, which can cause an 
increase in cytokine expression[21]. While there are an in-
sufficient number of  studies conducted on S. boulardii, S. 
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boulardii is believed to be involved in anti-inflammatory 
effects by affecting various inflammatory mechanisms[5-7].
In conclusion, this study establishes that S. boulardii 
does not improve DAI or colonic inflammation in rats 
with TNBS-induced colitis and does not reduce serum 
or tissue TNF-α levels. The only significant effect of  S. 
boulardii is reducing tissue NO levels. S. boulardii-based 




It is thought that inflammatory bowel disease (IBD) develops in genetically 
prone individuals as a result of a defective immune response against the an-
tigens of enteric bacterial flora. Antibiotics and immunomodulatory therapies 
play an important role in the treatment of these diseases. Saccharomyces 
boulardii (S. boulardii) is a probiotic yeast, and it is known that probiotics inhibit 
pathogenic invasion and demonstrate regulatory effects on the enteric flora and 
immune system. Although there are several published studies on the use of 
probiotic bacterial therapy in experimental animals with induced IBD, there are 
a few studies on the involvement of S. boulardii.
Research frontiers
The present study shows that S. boulardii is a probiotic agent that demonstrates 
no effects on the disease activity index (DAI), serum and tissue tumor necrosis 
factor-α (TNF-α) levels, or pathologic findings in a rat model of trinitrobenzene 
sulfonic acid (TNBS)-induced colitis. However S. boulardii may reduce tissue 
nitric oxide (NO) levels, which is an important messenger involved in vein per-
meability and tissue damage. S. boulardii-based fungemia was not detected.
Innovations and breakthroughs
There are a few clinical studies on the efficacy of S. boulardii for treating IBD. 
Based on the findings of these published studies, S. boulardii appears to be 
promising. In a recent study, it was shown that treating human colon epithelial 
cells with S. boulardii increases the expression of peroxisome proliferator-
activated receptor-c and inhibits the secretion of IL-8. In the same study, it was 
demonstrated that S. boulardii decreases intestinal inflammation by reducing 
the mucosal expression of proinflammatory cytokines in rats with TNBS-induced 
colitis. However the effects of S. boulardii on DAI and NO were not evaluated. 
The present study was conducted to investigate the effects of S. boulardii on 
DAI, pathological scores, TNF-α, and NO. Additionally, the risk of fungemia, 
which could result from treatment with S. boulardii alone or in combination with 
corticosteroids, was also evaluated.
Applications
The present study shows that S. boulardii does not improve DAI or colonic 
inflammation in rats with TNBS-induced colitis or reduce TNF-α levels. These 
results suggest that S. boulardii may not be an effective treatment for patients 
with IBD. In contrast, the limited number of studies conducted on this issue 
have reported some promising results. Therefore, further studies are needed in 
order to draw a firm conclusion.
Terminology
Crohn’s disease and ulcerative colitis, both of which are referred to as IBD, are 
chronic inflammatory disorders of the gastrointestinal tract that have character-
istic clinical, pathological, endoscopic, and radiological features. TNBS-induced 
colitis is well-established in various animal models of mucosal inflammation that 
have been used for over 2 decades for the study of IBD pathogenesis and in 
preclinical studies. Probiotics are live microorganisms that positively affect health 
when ingested. S. boulardii is a live yeast that is extensively used as a probiotic.
Peer review
This study examine the impact of S. boulardii on TNBS colitis. This is an excel-
lent experimental study that evaluated the effects of S. boulardii on clinical ac-
tivity scores, TNF-α levels, serum and tissue NO levels, and macroscopic and 
microscopic pathological scores in a rat model of TNBS-induced colitis.
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